Healius Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Paul Anderson

Algemeen directeur

AU$944.6k

Totale compensatie

Percentage CEO-salaris	97.7%
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.6yrs
Gemiddelde ambtstermijn bestuur	2.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Paul Anderson's beloning veranderd ten opzichte van Healius's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$945k	AU$923k	-AU$636m
Dec 31 2023	n/a	n/a	-AU$984m
Sep 30 2023	n/a	n/a	-AU$682m
Jun 30 2023	AU$235k	AU$194k	-AU$380m

Compensatie versus markt: De totale vergoeding ($USD 625.70K ) Paul } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 1.11M ).

Compensatie versus inkomsten: De vergoeding van Paul is gestegen terwijl het bedrijf verliesgevend is.

CEO

Paul Anderson

less than a year

Tenure

AU$944,623

Compensatie

Mr. Paul D. Anderson, B COMM, CA serves as Managing Director, Chief Executive Officer since 2024 at Healius Limited and had been Group Chief Financial Officer of Healius Limited since March 1, 2023 and als...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Anderson	MD, CEO & Director	less than a year	AU$944.62k	geen gegevens
Stephen Humphries	CFO& Company Secretary	1.7yrs	AU$718.57k	0.0024% A$ 26.9k
Jan Van Rooyen	Head & Group Executive of Healius Pathology	1.4yrs	AU$1.43m	geen gegevens
Paula Bayliss	Group Executive of People & Culture	less than a year	geen gegevens	geen gegevens
John McKechnie	Advisor	5.3yrs	AU$275.71k	0% A$ 0
Phil Lucas	Chief Executive of Lumus Imaging	1.8yrs	geen gegevens	geen gegevens
Ian Mcphan	Chief Operating Officer of Healius Pathology	no data	geen gegevens	geen gegevens
Sharon Ng	Head of Group FP&A	no data	geen gegevens	geen gegevens
Arjun Narang	Group Executive of Operations Transformation	1.5yrs	geen gegevens	geen gegevens
Jon Eide	Group Executive of Commercial & Customer	1.6yrs	geen gegevens	geen gegevens
Alejandro Rosales	Head of Digital Strategy & Delivery Office	no data	geen gegevens	geen gegevens
Mary Weaver	Company Secretary	1.7yrs	geen gegevens	geen gegevens

1.6yrs

Gemiddelde duur

Ervaren management: Het managementteam van HLS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.6 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Anderson	MD, CEO & Director	less than a year	AU$944.62k	geen gegevens
Gordon Davis	Non-Executive Director	9.3yrs	AU$180.18k	0.017% A$ 191.4k
Kathryn McKenzie	Interim Non-Executive Independent Chair	3.8yrs	AU$269.98k	0.014% A$ 156.7k
Michael Stanford	Independent Non-Executive Director	1.2yrs	AU$138.74k	0.0045% A$ 50.8k
Sally Evans	Independent Non-Executive Director	6.3yrs	AU$185.00k	0.013% A$ 150.9k
John Mattick	Non Executive & Independent Director	2.7yrs	AU$170.00k	0.0075% A$ 85.0k
Charlie Taylor	Independent Non-Executive Director	1.7yrs	AU$174.82k	0.018% A$ 208.0k

2.7yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HLS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.7 jaar), wat duidt op een nieuw bestuur.

Healius Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Healius Limited, Annual General Meeting, Nov 15, 2024

Healius Limited Announces Step Down of Ravi Jeyaraj as Non-Executive Director, Effective 2 August 2024

High number of new directors

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Recent updates

Price target increased by 14% to AU$1.77

Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million.

Price target increased by 8.4% to AU$1.68

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Healius Limited, Annual General Meeting, Nov 15, 2024

Price target increased by 7.5% to AU$1.51

Full year 2024 earnings: Revenues exceed analyst expectations

TPG Capital, PEP Reportedly Still Competing for Healius Lumus Imaging

Final Bids Reportedly Expected for Healius

Healius Limited Announces Step Down of Ravi Jeyaraj as Non-Executive Director, Effective 2 August 2024

Macquarie Unit Reportedly in Healius Race

Healius Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Sonic in the Running for Healius Imaging Business

Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit

High number of new directors

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Australian Clinical Labs Limited (ASX:ACL) cancelled the acquisition of Healius Limited (ASX:HLS) from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.

New minor risk - Shareholder dilution

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited, Annual General Meeting, Nov 01, 2023

Australian Clinical Labs Limited (ASX:ACL) canceled the acquisition of Healius Limited (ASX:HLS)

Healius Limited Appoints Michael Stanford as Director

Full year 2023 earnings: Revenues miss analyst expectations

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 37%

Consensus EPS estimates fall by 37%

Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023

Consensus EPS estimates increase by 34%

Consensus EPS estimates increase by 36%

Consensus EPS estimates increase by 22%

High number of new directors

Consensus EPS estimates increase by 18%

Is Healius Limited (ASX:HLS) Trading At A 50% Discount?

Independent Non Executive Chairman recently bought AU$103k worth of stock

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Consensus EPS estimates increase by 17%

Healius Limited Announces Resignation of Alison Stephenson as Company Secretary

Consensus EPS estimates fall by 21%

At AU$3.07, Is It Time To Put Healius Limited (ASX:HLS) On Your Watch List?

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Consensus forecasts updated

Price target decreased to AU$3.23

Consensus EPS estimates fall by 13%

Nexus Hospitals entered into an agreement to acquire Montserrat Healthcare Pty Ltd from Healius Limited (ASX:HLS).

Here's Why Healius (ASX:HLS) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 27%

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

MD, CEO & Director recently sold AU$660k worth of stock

Is Now An Opportune Moment To Examine Healius Limited (ASX:HLS)?

Brookfield Reportedly Drops Out of Race to Buy Healius

Independent Non Executive Director recently bought AU$86k worth of stock

Non Executive & Independent Director recently bought AU$70k worth of stock

MD, CEO & Director exercised options to buy AU$2.2m worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Healius Limited Announces Fully Franked Ordinary Paid Dividend for the Six Months Ended June 30, 2022, Payable on September 21, 2022

Healius Limited, Annual General Meeting, Oct 20, 2022

Are Investors Undervaluing Healius Limited (ASX:HLS) By 48%?

Healius Reportedly Launches Day Surgery Sale Process

Price target decreased to AU$4.30

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Consensus EPS estimates fall by 13%

Healius Limited to Report Fiscal Year 2022 Results on Aug 31, 2022

Why Healius Limited (ASX:HLS) Could Be Worth Watching